Epitope Conservation of AZD5148, a Broadly Neutralizing Anti-Toxin B Monoclonal Antibody, Among Diverse and Global Contemporary Clostridioides difficile Isolates
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiaf423 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Kelly Ann Mahool und 11 weiteren Autor:innen. Beteiligte Einrichtung: Bioinformatics, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland. Hauptthemen laut MEDLINE: Clostridioides difficile, Bacterial Toxins, Epitopes, Bacterial Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Background
Clostridioides difficile toxin B is a virulence factor for C. difficile infections and a clinically validated target for prevention of C. difficile infection recurrence. AZD5148 is a toxin B–neutralizing human monoclonal antibody that binds to an epitope on the toxin B glucosyltransferase domain. Herein, we aim to evaluate the conservation of this binding epitope using a collection of 9134 global C. difficile genomes obtained from a public repository to confirm that residues that are crucial for neutralization are conserved.
Methods
Using isolates collected between 2015 and 2023 from 2 independent sources, we performed variant calling, sequence typing, and phylogenetic analysis. We tested in vitro neutralization of cytotoxicity by AZD5148 using 2 cell lines.
Results
Herein, we showed that the AZD5148 epitope is highly conserved across all geographic regions and sequence types and has a higher average conservation frequency in its binding site (99.58%) when compared with bezlotoxumab (82.47%). AZD5148 also exhibited broad neutralization in vitro against 8 recently circulating ribotypes.
Conclusions
Our comprehensive analysis of global sequences found the AZD5148 epitope to be highly conserved and thus unlikely to be affected by most genotypic variations in recently circulating C. difficile ribotypes and sequence types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioinformatics, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.
- Bacteriology, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.
- Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.
- Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
ORCID-Profile: Emily Nguyen, Victoria Godfrey, Christine Tkaczyk, Vancheswaran Gopalakrishnan
Förderung
- AstraZeneca
Zitieren
APA
Mahool, K. A., Nguyen, E., Godfrey, V., Stanley, A. M., Brady, T., Gamson, A., Rosenthal, K., Green, J., Podlaha, O., Sellman, B. R., Tkaczyk, C., & Gopalakrishnan, V. (2025). Epitope Conservation of AZD5148, a Broadly Neutralizing Anti-Toxin B Monoclonal Antibody, Among Diverse and Global Contemporary Clostridioides difficile Isolates. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf423
Vancouver
Mahool KA, Nguyen E, Godfrey V, Stanley AM, Brady T, Gamson A, et al. Epitope Conservation of AZD5148, a Broadly Neutralizing Anti-Toxin B Monoclonal Antibody, Among Diverse and Global Contemporary Clostridioides difficile Isolates. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf423
BibTeX
@article{Mahool2025,
author = {Mahool, Kelly Ann and Nguyen, Emily and Godfrey, Victoria and Stanley, Ann Marie and Brady, Tyler and Gamson, Adam and Rosenthal, Kim and Green, Justin and Podlaha, Ondrej and Sellman, Bret R and Tkaczyk, Christine and Gopalakrishnan, Vancheswaran},
title = {Epitope Conservation of AZD5148, a Broadly Neutralizing Anti-Toxin B Monoclonal Antibody, Among Diverse and Global Contemporary Clostridioides difficile Isolates},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiaf423}
}
EUVIMED